National Institute of Allergy and Infectious Diseases - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability of a rectal microbicide douche containing the antiretroviral drug tenofovir to prevent HIV infection spread among men.

Drugs Health Pharma

Mid-stage trial of a rectal microbicide for HIV prevention in the US begins

HQ Team November 3, 2024: The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability.

by HealthQuill
November 3, 2024
0 Comments

Read More

Antibodies to target a hard-to-spot region or the “dark side” of the influenza virus were discovered by researchers, and may pave new vaccines and therapies to fight the disease.

Drugs Health Pharma

Antibody discovery may aid new vaccines, therapies to fight influenza

HQ Team March 3, 2024: Antibodies to target a hard-to-spot region or the “dark side” of the influenza virus were discovered by researchers,.

by HealthQuill
March 3, 2024
0 Comments

Read More

Human trials to stop radioactive contaminants begin

Drugs Health Medical Pharma

Human trials to stop radioactive contaminants in body begin

HQ Team May 17, 2023: The first trial on humans of an experimental oral drug for removing radioactive contaminants from inside the body.

by HealthQuill
May 17, 2023
0 Comments

Read More